FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA OKs Less-Frequent Dosing Schedule for Lillys Ebglyss

FDA approves an expanded dosing regimen for Lillys atopic dermatitis treatment Ebglyss (lebrikizumab-lbkz), allowing certain patients with moderate-to...

latest-news-card-1
FDA General

FDA Cites Formulated Solutions Over Manufacturing, Quality

FDA sends an untitled letter to contract manufacturer Formulated Solutions, citing GMP violations related to component testing and quality oversight a...

latest-news-card-1
Human Drugs

Gilead/Merck Stop Trodelvy/Keytruda Study

Gilead and Merck say they have discontinued the KEYNOTE-D46/EVOKE-03 study of Gileads Trodelvy and Mercks Keytruda as a treatment for certain patients...

latest-news-card-1
Human Drugs

CGMP Violations Found in Zydus Record Review

FDA warns Indias Zydus Lifesciences Limited about CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Human Drugs

CGMP Issues Cited at Hubei Gedian Humanwell

FDA warns Chinas Hubei Gedian Humanwell Pharmaceutical Co. about significant CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

FDA Reinspection of Troubled Novo Nordisk Facility

FDA documents GMP issues at a long-troubled Bloomington, IN, fill-finish facility formerly owned by Catalent and acquired by Novo Nordisk in late 202...

latest-news-card-1
Human Drugs

Disc Medicine Says FDA Open to Bitopertin Approval Path

Disc Medicine says it has reached agreement with FDA on a potential regulatory path forward for its investigational therapy bitopertin after receiving...

latest-news-card-1
Human Drugs

Senators Introduce Bill for Homeopathic Product Pathway

Senators Mike Lee (R-UT) and Tommy Tuberville (R-AL) introduce the Homeopathic Drug Product Safety, Quality, and Transparency Act.

latest-news-card-1
Human Drugs

Lilly's Oral GLP-1 Outperforms Oral Semaglutide in Diabetes Trial

Eli Lilly reports Phase 3 study results showing its oral GLP-1 receptor agonist Foundayo (orforglipron) outperformed Novo Nordisk's oral semaglutide o...

latest-news-card-1
FDA General

AMA Delegates Call for Tighter FDA Oversight of Unapproved Peptides

Delegates at the American Medical Association's annual meeting vote to support stronger FDA oversight of synthetic peptide products, citing growing co...